Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AP-303 by Shanghai Alebund Pharmaceuticals for Diabetic Nephropathy: Likelihood of Approval
AP-303 is under clinical development by Shanghai Alebund Pharmaceuticals and currently in Phase I for Diabetic Nephropathy. According to GlobalData,...
Data Insights
AP-303 by Shanghai Alebund Pharmaceuticals for Diabetic Nephropathy: Likelihood of Approval
AP-303 is under clinical development by Shanghai Alebund Pharmaceuticals and currently in Phase I for Diabetic Nephropathy. According to GlobalData,...